Erratum To: Single-Agent Bevacizumab Is an Effective Treatment in Recurrent Glioblastoma

Medical Oncology - United States
doi 10.1007/s12032-015-0482-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Bevacizumab and Chemotherapy for Recurrent Glioblastoma: A Single-Institution Experience

Neurology
Neurology
2009English

Bevacizumab in the Treatment of Glioblastoma: Is There an Optimal Dose or Schedule?

2012English

Sustained Focal Antitumor Activity of Bevacizumab in Recurrent Glioblastoma

Neurology
Neurology
2014English

Addition of Lomustine for Bevacizumab-Refractory Recurrent Glioblastoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2014English

Single-Institution Retrospective Review of Patients With Recurrent Glioblastoma Treated With Bevacizumab in Clinical Practice

Health Science Reports
2019English

Tumor Cell Response to Bevacizumab Single Agent Therapy in Vitro

Cancer Cell International
Cancer ResearchOncologyGenetics
2013English

Antiangiogenic Agents in the Treatment of Recurrent or Newly Diagnosed Glioblastoma: Analysis of Single-Agent and Combined Modality Approaches

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2011English

Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2016English

Single Agent Therapy With Bevacizumab for the Treatment of Atypical Choroid Plexus Tumor

Kansas Journal of Medicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy